Oncology Billing, Credentialing

Oncology practices bill for some of the most expensive services in outpatient medicine. A single treatment visit can include an infusion billed by the hour, several drugs billed by the unit, hydration, an E/M visit, and a lab component, and every piece follows its own coding rules. When a claim for a high-cost regimen gets denied, the practice has already bought and administered the drug.

Reimbursement in this specialty doesn’t sit still. Payers add prior authorization requirements as new therapies launch, Medicare adjusts its drug billing rules, and value-based payment models tie more oncology revenue to cost and quality measures.

Key Takeaways

What Makes Oncology Billing Different

Cancer patients rarely see one provider. Within a single month a patient might see a medical oncologist, a surgeon, a radiation oncologist, and a pathologist, across an office, an infusion center, and a hospital outpatient department. Each setting has its own place-of-service rules, and each specialist’s documentation has to support the others for the claims to hold up.

On the diagnosis side, ICD-10 guidelines put Z51.11 first when an encounter is solely for chemotherapy, with the cancer code listed after it. The malignancy code also has to fit the drug. Payer coverage policies list the diagnoses each drug is covered for, and a claim outside that list gets denied regardless of how well the administration was coded.

Chemotherapy and infusion administration

Chemotherapy administration codes are time-based and hierarchical. The first hour of an IV chemotherapy infusion bills as 96413, each additional hour as 96415, and a sequential infusion of a different drug as 96417. Only one initial service code is allowed per encounter, so when a patient gets hydration, a pre-medication push, and a chemotherapy infusion on the same day, the chemo infusion takes the initial code and everything else bills as an add-on. Hydration that runs at the same time as the chemotherapy isn’t separately billable at all.

An infusion record without start and stop times leaves the coder unable to support any of this.

Drug billing and units

Oncology drugs bill under HCPCS J-codes, and each code carries a fixed dosage per unit. A drug coded at 10 mg per unit and given at 450 mg bills as 45 units. Get the conversion wrong and the claim either underpays or trips a medically unlikely edit.

Medicare also requires the JW modifier on a separate line for any amount discarded from a single-dose vial, and the JZ modifier when nothing was discarded. Since most Part B drugs pay at average sales price plus 6 percent, the unit count on each line drives most of what the practice recovers for the drug. Patients who continue treatment at home move to a different billing model, which we cover under home infusion therapy.

Radiation oncology

Radiation therapy bills as a series of separate steps: clinical treatment planning (77261 to 77263), simulation (77280 to 77290), dosimetry and treatment devices, treatment delivery, and weekly treatment management (77427). Payers expect the record to document each step on the claim, and treatment management bills once for every five fractions delivered. The imaging used for staging and planning bills separately under radiology.

Clinical trials

When a patient enrolls in a clinical trial, the claim has to separate routine care, which Medicare and most commercial plans cover, from investigational services, which the trial sponsor usually pays for. Medicare claims for trial patients need the Q1 modifier on routine services, the Q0 modifier on investigational items, diagnosis code Z00.6, and the trial’s eight-digit NCT number. Leaving any of these off sends the claim back.

Common CPT and HCPCS Codes in Oncology

Oncology claims draw on a wide range of CPT codes across E/M, procedures, radiation, and drug administration. These come up on most oncology claims:

Correct codes on a claim with missing infusion times or the wrong drug units still get denied, so documentation review happens before coding, not after.

Prior Authorization and Denials

Most newer oncology drugs, including immunotherapies and targeted therapies, need prior authorization before the first dose. Oral oncolytics usually run through the pharmacy benefit and a specialty pharmacy, while infused drugs run through the medical benefit. One patient can end up with two separate authorization processes for a single treatment plan.

An approval on file doesn’t guarantee payment. If the regimen changes mid-cycle, the dose is adjusted for weight, or a biosimilar is substituted for the authorized brand, the claim no longer matches what the payer approved. We cover how this happens in why an approved authorization can still end in a denied claim.

These edits push the oncology denial rate above most other specialties. Running eligibility and benefits checks before each new regimen catches plan changes early. When a denial does come in, the appeal has to carry the medical necessity record that payer asks for, including pathology, staging, and prior lines of therapy.

Reimbursement Pressures on Oncology Practices

Hospital-owned oncology practices watch site-neutral payment policy closely. CMS and Congress have repeatedly considered paying hospital outpatient departments the same rate as physician offices for the same service, and drug administration has come up in several of those proposals. Practices billing as hospital outpatient departments would absorb most of that cut.

Patients are carrying more of the cost. High deductibles, coinsurance on specialty-tier drugs, and out-of-pocket maximums that reset every January can leave a patient owing thousands before the plan pays anything. Practices that estimate patient responsibility before treatment starts and enroll eligible patients in manufacturer and foundation assistance programs collect more of what’s owed.

Some of the repetitive work, like eligibility checks and claim status inquiries, can run through robotic process automation, which leaves billing staff more time for denials and authorizations.

Oncology Credentialing

Board certification and hospital privileges

Payers verify board certification in the provider’s subspecialty: medical oncology or hematology through the ABIM, radiation oncology through the American Board of Radiology, and complex general surgical oncology through the American Board of Surgery. Oncologists who treat at a hospital or an NCI-designated cancer center also need current privileges there, and some payers check those affiliations during enrollment.

Enrolling NPs, PAs, and new oncologists

Nurse practitioners and physician assistants often handle infusion visits and follow-ups, and each one needs their own payer enrollment before services can bill under their NPI. A new oncologist joining a group needs enrollment with every payer the group participates in, and that provider’s claims can’t go out until each one is approved. We explain that dependency in why you can’t bill what you can’t credential, and how long credentialing takes depends heavily on the payer mix.

Keeping profiles current

DataSpring/CAQH profiles need reattestation every 120 days, and a lapsed attestation can stall a recredentialing review. Oncologists who add an infusion location or join a new hospital also need those changes reported to every payer. Our credentialing specialists track these dates for every provider on a practice’s roster.

Oncology Billing FAQs

Why Oncology Practices Choose Medwave for Billing & Credentialing

Medwave handles oncology billing, credentialing, and payer contracting under one team, so a drug claim held up by an enrollment gap gets fixed by people who can see both sides. Our coders work infusion records hour by hour and check drug units against each HCPCS descriptor before a claim goes out, which is how we hold a 98% clean claim rate.

Our credentialing team averages a 60-day turnaround and tracks reattestation and recredentialing dates for every oncologist, NP, and PA we enroll. For practices renegotiating payer contracts, our contracting team works from the practice’s real drug and administration volume rather than a generic fee schedule.

Contact Medwave below to see how we can support your oncology practice.